2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax Oct 29, 2023
2023 ESH Poster – Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy as Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Oct 29, 2023
2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia Dec 11, 2022
2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies Dec 11, 2022
